EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single-institutional cohort study

Nikolaus B Wagner, Sarah M Knierim, Felix Luttermann, Gisela Metzler, Amir S Yazdi, Jürgen Bauer, Maximilian Gassenmaier, Andrea Forschner, Ulrike Leiter, Teresa Amaral, Claus Garbe, Thomas K Eigentler und 2 weitere

Journal of the American Academy of Dermatology · 2024

DOI: 10.1016/j.jaad.2023.11.040 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of the American Academy of Dermatology, 2024. Verfasst von Nikolaus B Wagner und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Allergology, Kantonsspital St. Gallen, St. Gallen, Switzerland; Department of Dermatology, Eberhard Karls …. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Sentinel Lymph Node. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Histopathologic regression of cutaneous melanoma is considered a favorable prognostic factor, but its significance in clinical practice remains controversial. OBJECTIVE: To investigate the prognostic importance of regression in patients with primary cutaneous melanoma undergoing sentinel lymph node (SLN) biopsy and to assess its significance in patients progressing to an unresectable stage requiring systemic therapy. METHODS: We retrospectively reviewed patients with newly diagnosed melanoma undergoing SLN biopsy between 2010 and 2015 and available information on histopathologic regression (n = 1179). Survival data and associations of clinical variables with SLN status were assessed. RESULTS: Patients with regressive melanoma showed favorable relapse-free (hazard ratio [HR], 0.52; P = .00013), distant metastasis-free (HR, 0.56; P = .0020), and melanoma-specific survival (HR, 0.35; P = .00053). Regression was associated with negative SLN (odds ratio, 0.48; P = .0077). In patients who progressed to an unresectable stage, regression was associated with favorable progression-free survival under immune checkpoint inhibition (HR, 0.43; P = .031) but not under targeted therapy (HR, 1.14; P = .73) or chemotherapy (HR, 3.65; P = .0095). LIMITATIONS: Retrospective, single-institutional design. CONCLUSIONS: Regression of cutaneous melanoma is associated with improved prognosis in patients eligible for SLN biopsy as well as in patients with unresectable disease receiving systemic therapy with immune checkpoint inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsSentinel Lymph NodeHumansSentinel Lymph Node BiopsyImmune Checkpoint InhibitorsRetrospective StudiesCohort StudiesProgression-Free SurvivalNeoplasm Recurrence, LocalPrognosis

Stichwörter der Autor:innen

chemotherapyclinical researchcutaneous melanomadrug responsehistopathologic regressionimmune checkpoint inhibitiononcologytargeted therapy

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, Venereology and Allergology, Kantonsspital St. Gallen, St. Gallen, Switzerland; Department of Dermatology, Eberhard Karls University of Tuebingen, Tuebingen, Germany. Electronic address: nikol…
  • Department of Dermatology, Venereology and Allergology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
  • Department of Dermatology, Eberhard Karls University of Tuebingen, Tuebingen, Germany.
  • Department of Dermatology, Eberhard Karls University of Tuebingen, Tuebingen, Germany; Center for Dermatohistopathology and Oral Pathology, Tuebingen/Wuerzburg, Tuebingen, Germany.
  • Department of Dermatology, Eberhard Karls University of Tuebingen, Tuebingen, Germany; Department of Dermatology and Allergology, RWTH University Hospital Aachen, Aachen, Germany.
  • Department of Dermatology, Eberhard Karls University of Tuebingen, Tuebingen, Germany; MVZ Dermatopathology, Friedrichshafen/Bodensee PartG, Friedrichshafen, Germany.

Zitieren

APA

Wagner, N. B., Knierim, S. M., Luttermann, F., Metzler, G., Yazdi, A. S., Bauer, J., Gassenmaier, M., Forschner, A., Leiter, U., Amaral, T., Garbe, C., Eigentler, T. K., Forchhammer, S., & Flatz, L. (2024). Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single-institutional cohort study. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2023.11.040

Vancouver

Wagner NB, Knierim SM, Luttermann F, Metzler G, Yazdi AS, Bauer J, et al. Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single-institutional cohort study. Journal of the American Academy of Dermatology. 2024. doi:10.1016/j.jaad.2023.11.040

BibTeX
@article{Wagner2024,
  author = {Wagner, Nikolaus B and Knierim, Sarah M and Luttermann, Felix and Metzler, Gisela and Yazdi, Amir S and Bauer, Jürgen and Gassenmaier, Maximilian and Forschner, Andrea and Leiter, Ulrike and Amaral, Teresa and Garbe, Claus and Eigentler, Thomas K and Forchhammer, Stephan and Flatz, Lukas},
  title = {Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single-institutional cohort study},
  journal = {Journal of the American Academy of Dermatology},
  year = {2024},
  doi = {10.1016/j.jaad.2023.11.040}
}
Kostenlos starten →